|
Volumn 24, Issue 3, 2003, Pages 113-114
|
Statins and myotoxicity [1]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ATORVASTATIN;
CERIVASTATIN;
CLOPIDOGREL;
CYTOCHROME P450 2C8;
CYTOCHROME P450 2C9;
CYTOCHROME P450 3A4;
FLUINDOSTATIN;
GEMFIBROZIL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MEVINOLIN;
PRAVASTATIN;
SIMVASTATIN;
PYRIDINE DERIVATIVE;
DRUG METABOLISM;
DRUG SAFETY;
FOOD DRUG INTERACTION;
HUMAN;
INCIDENCE;
KIDNEY FAILURE;
LETTER;
PATHOGENESIS;
PRIORITY JOURNAL;
RHABDOMYOLYSIS;
WORLD HEALTH ORGANIZATION;
AREA UNDER THE CURVE;
BIOAVAILABILITY;
CHEMICALLY INDUCED DISORDER;
AREA UNDER CURVE;
BIOLOGICAL AVAILABILITY;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
PYRIDINES;
RHABDOMYOLYSIS;
|
EID: 0037332357
PISSN: 01656147
EISSN: None
Source Type: Journal
DOI: 10.1016/S0165-6147(03)00022-1 Document Type: Letter |
Times cited : (7)
|
References (6)
|